None listed
Conditions
Interventions
Drug : Study Design
This is a prospective, randomized, multi-center study conducted in different Korean intensive care units (ICUs). This objective of the study is to evaluate the incidence of major d
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Understand and voluntarily sign an informed consent document prior to any study related assessment/procedures are conducted 2) First time histologically confirmed diagnosis of glioma (resection or biopsy) 3) Age =18 years and = 85 years 4) Glasgow Coma Score (GCS) 5-15
Exclusion criteria
Exclusion criteria: 1)Unable to perform the screening test due to the neurologic deficit 2)Evidence of ongoing acute brain bleeding on CT or MRI 3)Previously confirmed diagnosis of a benign, low- or high-grade brain tumor 4)Diagnosis of systemic cancer other than glioma (breast cancer, lung cancer, gastric cancer, colon cancer etc.) 5)Currently taking antidepressant drugs 6)Previously suffered from depression in the past or within 5 years of diagnosis, and currently do not receive drug therapy 7)Taking following drugs: MAO (monoamine oxidase) inhibitor, linezolid, thioridazine, mesoridazine, pimozide, tizanidine, terfenadine, astemizole or cisapride 8)SSRI allergic history 9)On antiplatelets or anticoagulation agents (aspirin, clopidogrel, cilostazol, heparin, warfarin ?vitamin K antagonist?, DOAC ?Direct Oral Anticoagulants?) 10)On non-steroidal anti-inflammatory drug (NSAID) 11)High bleeding risk patients: hematologic disorder, thrombocytopenia ( < 50, 000/µL), coagulopathy 12)History of coronary artery disease or gastrointestinal (GI) bleeding 13)Post-anoxic coma; status epilepticus; Parkinson; central nervous system (CNS) infections (community-acquired; hospital-acquired; ventriculitis; post-operative) 14)Pregnancy or breastfeeding patient 15)Life expectancy less than 3 month 16)DNR (do not resuscitate) ordered patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Cognitive impair scale;Neurologic deficit | — |
Countries
Korea, Republic of
Contacts
Public ContactMoinay Kim
University of Ulsan
Outcome results
None listed